- Home
- MUC vs NBTX Comparison
MUC vs NBTX Comparison
Compare MUC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUC
- NBTX
- Stock Information
- Founded
- MUC 1997
- NBTX 2003
- Country
- MUC United States
- NBTX France
- Employees
- MUC N/A
- NBTX N/A
- Industry
- MUC Investment Bankers/Brokers/Service
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- MUC Finance
- NBTX Health Care
- Exchange
- MUC Nasdaq
- NBTX Nasdaq
- Market Cap
- MUC 962.6M
- NBTX 868.8M
- IPO Year
- MUC N/A
- NBTX 2020
- Fundamental
- Price
- MUC $10.74
- NBTX $28.57
- Analyst Decision
- MUC
- NBTX Strong Buy
- Analyst Count
- MUC 0
- NBTX 1
- Target Price
- MUC N/A
- NBTX $8.00
- AVG Volume (30 Days)
- MUC 292.8K
- NBTX 130.5K
- Earning Date
- MUC 01-01-0001
- NBTX 09-30-2025
- Dividend Yield
- MUC 4.19%
- NBTX N/A
- EPS Growth
- MUC N/A
- NBTX N/A
- EPS
- MUC N/A
- NBTX N/A
- Revenue
- MUC N/A
- NBTX $11,930,711.00
- Revenue This Year
- MUC N/A
- NBTX N/A
- Revenue Next Year
- MUC N/A
- NBTX $74.67
- P/E Ratio
- MUC N/A
- NBTX N/A
- Revenue Growth
- MUC N/A
- NBTX N/A
- 52 Week Low
- MUC $9.19
- NBTX $2.76
- 52 Week High
- MUC $11.30
- NBTX $27.77
- Technical
- Relative Strength Index (RSI)
- MUC 55.15
- NBTX 82.00
- Support Level
- MUC $10.68
- NBTX $20.15
- Resistance Level
- MUC $10.88
- NBTX $22.64
- Average True Range (ATR)
- MUC 0.10
- NBTX 1.73
- MACD
- MUC -0.02
- NBTX 1.08
- Stochastic Oscillator
- MUC 43.18
- NBTX 94.03
About MUC Blackrock MuniHoldings California Quality Fund Inc.
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment firm. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.